Clinical Trial

Prospective Validation of the STOPSHOCK Score - Artificial Intelligence Based Predictive Scoring System to Identify the Risk of Developing Cardiogenic Shock (CS) in Patients Suffering From Acute Coronary Syndrome (ACS)

Study acronym: STOPSCHOCK
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Cardiogenic shock (CS) is a severe complication of acute coronary syndrome (ACS) with mortality approaching 50% despite the use of percutaneous mechanical circulatory support devices (pMCS). Identifying high-risk patients prior to the development of CS could allow pre-emptive use of pMCS possibly preventing CS. For this purpose, we derived and externally validated a machine learning score to predict in-hospital CS in patients with ACS with c-statistics: 0.844 (95% confidence interval, 0.841-0.847). STOPSCHOCK score is available as a web or smartphone application. The aim of this study is to prospectively validate the STOPSHOCK score on a large cohort of ACS patients in a real- world clinical environment.
Trial Details
NCT Number NCT07090382
Lead Sponsor Premedix Academy
Conditions Cardiogenic Shock, Cardiogenic Shock Acute, Cardiogenic Shock Post Myocardial Infarction, Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), PCI
Enrollment 1,046 participants
Start Date 2025-06-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-29